Table 5. Quality of evidence and summary assessment of the included in vitro studies according to the modified CONSORT checklist.
| Study (yr) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Summary assessment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stubinger et al. [33] (2007) | + | ? | + | + | − | n/a | n/a | n/a | − | + | ? | ? | + | − | High |
| Vigolo et al. [35] (2010) | + | + | + | + | − | n/a | n/a | n/a | + | + | + | + | − | − | Low |
| Seol et al. [32] (2012) | + | ? | + | + | − | n/a | n/a | n/a | − | + | + | + | + | − | Low |
| Checketts et al. [26] (2014) | + | + | + | + | − | n/a | n/a | n/a | − | + | + | + | − | − | Low |
| Miranda et al. [30] (2014) | + | ? | − | − | − | n/a | n/a | n/a | − | − | ? | + | + | − | High |
| Kushima et al. [28] (2016) | + | ? | + | + | − | n/a | n/a | n/a | − | + | + | ? | + | − | Unclear |
| Lang et al. [29] (2016) | + | + | + | ? | + | n/a | n/a | n/a | − | + | + | + | + | − | Low |
| Vigolo et al. [34] (2017) | + | + | + | + | − | n/a | n/a | n/a | + | + | + | + | − | − | Low |
| Nakazawa et al. [31] (2018) | + | + | + | + | − | n/a | n/a | n/a | − | + | + | + | + | − | Low |
| Alhaidary et al. [25] (2019) | + | ? | + | ? | − | n/a | n/a | n/a | − | + | ? | + | + | − | High |
| Huang et al. [27] (2019) | + | + | + | + | − | n/a | n/a | n/a | − | + | ? | + | + | − | Low |
+: low risk of bias, ?: unclear risk of bias, −: high risk of bias, n/a: not applicable.